Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Megan E. Zavorka Thomas"'
Autor:
Jae Yoon Jeon, Daelynn R. Buelow, Dominique A. Garrison, Mingshan Niu, Eric D. Eisenmann, Kevin M. Huang, Megan E. Zavorka Thomas, Robert H. Weber, Clifford J. Whatcott, Steve L. Warner, Shelley J. Orwick, Bridget Carmichael, Emily Stahl, Lindsey T. Brinton, Rosa Lapalombella, James S. Blachly, Erin Hertlein, John C. Byrd, Bhavana Bhatnagar, Sharyn D. Baker
Publikováno v:
JCI Insight, Vol 5, Iss 23 (2020)
Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK signaling,
Externí odkaz:
https://doaj.org/article/4bacc087740b4a43a3e2e850f46e9e4b
Autor:
Megan E. Zavorka Thomas, Navjot Pabla, Daelynn R. Buelow, Sharyn D. Baker, Alex Sparreboom, Jae Yoon Jeon, Josie A. Silvaroli, Moray J. Campbell, Zahra Talebi
Publikováno v:
Blood Advances. 5:5041-5046
Drug resistance and relapse are common challenges in acute myeloid leukemia (AML), particularly in an aggressive subset bearing internal tandem duplications (ITDs) of the FLT3 receptor (FLT3-ITD+). The tyrosine kinase inhibitor gilteritinib is approv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb604fc79537e224f88db281ce881ca5
https://doi.org/10.1182/bloodadvances.2021005614
https://doi.org/10.1182/bloodadvances.2021005614
Autor:
Jae Yoon Jeon, Alice A. Gibson, Alex Sparreboom, Xiyuan Lu, Alessia Lodi, Julie Nguyen, Sharyn D. Baker, Meghan Collins, Douglas H. Sweet, Zahra Talebi, Muhammad Erfan Uddin, Daelynn R. Buelow, Rosa Lapalombella, Shannon R. Sweeney, Moray J. Campbell, Stefano Tiziani, Megan E. Zavorka Thomas, Lindsey T. Brinton
Publikováno v:
Molecular Cancer Therapeutics. 20:2207-2217
Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy associated with frequent relapse and poor overall survival. The tyrosine kinase inhibitor gilteritinib is approved for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dde5311b9b47f03214c1a1c35b1cc7d
https://doi.org/10.1158/1535-7163.mct-21-0071
https://doi.org/10.1158/1535-7163.mct-21-0071
Autor:
Megan E. Zavorka Thomas, Eric D. Eisenmann, Muhammad Erfan Uddin, Sherry H. Xia, Vincenzo Coppola, Markus Keiser, Yan Jin, Pearlly S. Yan, Paul W. Burridge, Sharyn D. Baker, Duncan DiGiacomo, Kevin M. Huang, Ralf Bundschuh, Tarek Magdy, Sakima A. Smith, Anne T. Nies, Taosheng Chen, Alexander Pan, Kara N. Corps, Daniel Addison, Moray J. Campbell, Qiang Fu, Alice A. Gibson, Alex Sparreboom, Stefan Oswald, Joanne Wang, Cynthia A. Carnes, Shuiying Hu, Maryam B. Lustberg, Yang Li, Marcus Otter, Ingrid M. Bonilla
Publikováno v:
Proc Natl Acad Sci U S A
Doxorubicin is a commonly used anticancer agent that can cause debilitating and irreversible cardiac injury. The initiating mechanisms contributing to this side effect remain unknown, and current preventative strategies offer only modest protection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a66cb6183037fdeb177f346573c042
https://europepmc.org/articles/PMC7865186/
https://europepmc.org/articles/PMC7865186/
Autor:
Megan E, Zavorka Thomas, Xiyuan, Lu, Zahra, Talebi, Jae Yoon, Jeon, Daelynn R, Buelow, Alice A, Gibson, Muhammad Erfan, Uddin, Lindsey T, Brinton, Julie, Nguyen, Meghan, Collins, Alessia, Lodi, Shannon R, Sweeney, Moray J, Campbell, Douglas H, Sweet, Alex, Sparreboom, Rosa, Lapalombella, Stefano, Tiziani, Sharyn D, Baker
Publikováno v:
Mol Cancer Ther
Acute myeloid leukemia (AML) with a FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy associated with frequent relapse and poor overall survival. The tyrosine kinase inhibitor gilteritinib is approved for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d7e2183b2a6d7a63eff63ac3f1eb7978
https://pubmed.ncbi.nlm.nih.gov/34518298
https://pubmed.ncbi.nlm.nih.gov/34518298
Autor:
Robert H. Weber, Dominique Garrison, James S. Blachly, Mingshan Niu, Daelynn R. Buelow, Megan E. Zavorka Thomas, Shelley Orwick, Steve L. Warner, Eric D. Eisenmann, Lindsey T. Brinton, Emily Stahl, Jae Yoon Jeon, Rosa Lapalombella, Erin Hertlein, John C. Byrd, Clifford J. Whatcott, Kevin M. Huang, Sharyn D. Baker, Bhavana Bhatnagar, Bridget Carmichael
Publikováno v:
JCI Insight, Vol 5, Iss 23 (2020)
JCI Insight
JCI Insight
Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK signaling,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de011dfcb9b0265b86697b0a6fe7594d
https://doaj.org/article/4bacc087740b4a43a3e2e850f46e9e4b
https://doaj.org/article/4bacc087740b4a43a3e2e850f46e9e4b
Autor:
Jae Yoon Jeon, James S. Blachly, Shelley Orwick, Eric D. Eisenmann, Navjot Pabla, Bhavana Bhatnagar, Daelynn R. Buelow, Sharyn D. Baker, Jack Stromatt, Bradley W. Blaser, Megan E. Zavorka Thomas
Publikováno v:
Blood. 138:207-207
While clinical benefit has been observed with gilteritinib in patients with FLT3 mutated relapsed/refractory acute myeloid leukemia (AML), most patients relapse through mechanisms that are incompletely understood. In this study, to investigate mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8710f7289a6c16933d022bf277c5557b
https://doi.org/10.1182/blood-2021-148569
https://doi.org/10.1182/blood-2021-148569
Autor:
Clifford J. Whatcott, Jae Yoon Jeon, Megan E. Zavorka Thomas, Sharyn D. Baker, Steve L. Warner, Bhavana Bhatnagar, Daelynn R. Buelow, Dominique Garrison, John C. Byrd
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c09c7176b50215f761255fccaae777c
https://doi.org/10.1096/fasebj.2019.33.1_supplement.675.4
https://doi.org/10.1096/fasebj.2019.33.1_supplement.675.4
Autor:
Mingshan Niu, Erin Hertlein, Megan E. Zavorka Thomas, Daelynn R. Buelow, Shelley Orwick, John C. Byrd, Sharyn D. Baker, Dominique Garrison, Clifford J. Whatcott, Bhavana Bhatnagar, Eric D. Eisenmann, Jae Yoon Jeon, Steven L. Warner
Publikováno v:
The FASEB Journal. 34:1-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e88ab57d1ecc7d66e7007862287b9c46
https://doi.org/10.1096/fasebj.2020.34.s1.02655
https://doi.org/10.1096/fasebj.2020.34.s1.02655
Autor:
Kevin M. Huang, Megan E. Zavorka Thomas, Alice A. Gibson, Alex Sparreboom, Mingqing Chen, Shuiying Hu, Maryam M. Lustburg, Yang Li, Jason A. Sprowl, Alix F. Leblanc
Publikováno v:
The FASEB Journal. 34:1-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b58bccb157e56bae609dae8a37870506
https://doi.org/10.1096/fasebj.2020.34.s1.04083
https://doi.org/10.1096/fasebj.2020.34.s1.04083